Atropos Health Named to the 2023 CB Insights’ Digital Health 50 List

Atropos Health recognized for achievements in Biomedical NLP

CB Insights today named Atropos Health to its fifth-annual Digital Health 50 (formerly the Digital Health 150), showcasing the 50 most promising private digital health companies of 2023.

"From bringing clinical trials to underserved populations to developing new drugs and therapies, this year’s Digital Health 50 winners are transforming the future of healthcare,” said Alex Lennox-Miller, CB Insights’ Lead Healthcare Analyst. “Generative AI is continuing to gain traction in healthcare, with over thirty companies in this year’s cohort offering AI-augmented solutions. We are excited to follow the meaningful impact, industry-leading innovations, and continued success of this year’s winners.”

“I am thrilled for the Atropos Health Team and its users and customers to receive this recognition,” said Co-Founder and CEO Dr. Brigham Hyde. “We are committed to providing evidence-based insights in order to drive better patient outcomes, accelerate drug discovery, and ultimately save healthcare and life science organizations significant time and expenses.”

The 50 winners were selected from a pool of over 10K companies, including applicants and nominees. They were chosen based on several factors, including CB Insights datasets — covering R&D activity, Mosaic scores, business relationships, software buyer transcripts, investor profiles, news sentiment analysis, competitive landscape, and team strength — along with criteria such as tech novelty, market potential, and impact on the industry.

Atropos Health is used by clinicians, researchers, physicians, and drug developers to close the global evidence gap while accelerating clinical trial and decision-making timelines. The company’s products include Geneva OS™(Generative Evidence Acceleration Operating System) and the ChatRWD™ (Real World Data) application, the first Generative AI application incorporating direct Chat-to-Database capability. These offerings enable non technical users to generate publication grade Observational Research studies leveraging deidentified patient level real world data from the Atropos Evidence Network in a matter of minutes, saving organizations valuable time, money, and staffing resources. Geneva OS and ChatRWD work alongside Atropos’ evidence solutions – the Green Button Informatics Consult Service, Atropos Evidence Network, and the Atropos Evidence Library.

Quick facts on the 2023 Digital Health 50:

• Equity funding and deals: Overall, the cohort has raised $3.2B+ over 145 equity deals since 2018. This includes nearly $1.5B over 41 deals in 2023 YTD.
• Unicorns: This year's list includes only 1 unicorn with a $1B+ valuation.
• Global Reach: This year's winners represent 8 countries across the globe. Twenty-two percent are headquartered outside the US, including 3 from the United Kingdom, 2 from Israel, and 2 from Spain. Other countries represented include South Korea, Belgium, France, and Brazil.

About CB Insights

CB Insights builds software that enables the world's best companies to discover, understand, and make technology decisions with confidence. By marrying data, expert insights, and work management tools, clients manage their end-to-end technology decision-making process on CB Insights. To learn more, please visit www.cbinsights.com.

About Atropos Health

Atropos Health is the developer of Geneva OS, the operating system for rapid healthcare evidence across a vast network of real world data. Health systems and life science companies work with Atropos to close evidence gaps from bench to bedside, elevate clinical outcomes with data-driven care, expedite research, and more. Our solutions offerings are based on many peer-reviewed publications, thousands of active users over the past decade, and on-staff clinical expertise. We aim to transform healthcare with timely, relevant real-world evidence.

To learn more about Atropos Health, visit www.atroposhealth.com or connect through LinkedIn or follow on X @AtroposHealth.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231205210653/en/